Professional Documents
Culture Documents
The trial achieved its primary endpoint of efficacy in preventing polymerase chain reaction (PCR)-confirmed,
symptomatic mild, moderate or severe COVID-19 with onset at least 7 days after the second dose. Solicited
adverse events were predominantly mild-to-moderate and transient, were more frequent in the vaccine
recipients and increased after the second dose. Severe reactions were infrequent and there were no safety
concerns related to vaccination.
The manuscript, ‘Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico,’ has also
been submitted for peer review. Initial findings from this study were shared on June 14.
https://ir.novavax.com/Complete-PREVENT-19-Phase-3-Clinical-Trial-Results-Manuscript-for-COVID-19-
Vaccine-Posted-to-medRxiv